8-K: Absci Reports Q3 2024 Financial Results and Business Updates, Highlights AI-Driven Drug Discovery Progress

Absci Corporation announced its third quarter 2024 financial results, showcasing progress in AI-driven drug discovery and key partnerships.

Summary

• Absci Corporation reported a revenue of $1.7 million for the third quarter of 2024, compared to $0.7 million in the same period of 2023, driven by partnered programs.
• Research and development expenses increased to $18.0 million, up from $11.0 million in the prior year, due to increased lab operations and IND-enabling studies for ABS-101.
• Selling, general, and administrative expenses decreased slightly to $9.3 million from $9.5 million year-over-year.
• The company's net loss for the quarter was $27.4 million, compared to a net loss of $22.0 million in the third quarter of 2023.
• Absci's cash, cash equivalents, and short-term investments totaled $127.1 million as of September 30, 2024, down from $145.2 million as of June 30, 2024.
• The company now expects a gross use of cash of approximately $75 million for the fiscal year ending December 31, 2024, which is lower than the previous estimate of $80 million.
• Absci believes its current cash reserves will fund operations into the first half of 2027.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments in partnerships and technology, the increased net loss and cash burn are concerning. The company's long cash runway and progress in key programs provide some optimism.

Positives

• Revenue increased significantly year-over-year, driven by progress in partnered programs.
• The company achieved a key milestone in its collaboration with AstraZeneca, demonstrating the effectiveness of its AI platform.
• A new partnership with Twist Bioscience expands the application of Absci's AI technology.
• Absci is making progress on its internal pipeline programs, with ABS-101 advancing towards clinical trials.
• The company has reduced its expected cash burn for the year.
• Current cash reserves are expected to fund operations into the first half of 2027, providing a long runway for development.
• Absci's AI platform is designed to optimize multiple parameters important to drug discovery and development, including affinity, specificity, and developability.
• The company's platform aims to reduce the time and cost to clinic, with an estimated 2 years and $14-16M from target to IND.

Negatives

• The company experienced a net loss of $27.4 million for the quarter, an increase compared to the $22.0 million loss in the same period last year.
• Cash reserves decreased from $145.2 million to $127.1 million during the quarter.
• Research and development expenses increased significantly, driven by increased lab operations and IND-enabling studies for ABS-101.

Risks

• The company's success is dependent on the ability to secure milestone payments and royalties from partnerships.
• Clinical trial results may not replicate positive preclinical findings.
• Absci relies on third parties for manufacturing and supply of preclinical and clinical materials.
• The company's ability to effectively collaborate with partners is crucial for the success of its programs.
• Market conditions and regulatory developments could impact the company's activities and partnerships.

Future Outlook

Absci believes its existing cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the first half of 2027. The company anticipates advancing its internal pipeline programs and securing additional drug creation partnerships.

Management Comments

• Sean McClain, Founder and CEO, stated that the recent progress across internal and partnered programs illustrates the company's commitment to delivering results.
• He highlighted the achievement of a milestone with AstraZeneca, the new partnership with Twist, and the advancement of internal programs as a period of solid execution for Absci.

Industry Context

Absci's focus on AI-driven drug discovery aligns with the growing trend of leveraging artificial intelligence to accelerate and improve the efficiency of drug development. The partnerships with AstraZeneca and Twist Bioscience demonstrate the industry's interest in Absci's unique platform and capabilities.

Comparison to Industry Standards

• Absci's AI-driven platform aims to significantly reduce the time and cost of drug discovery, targeting a 2-year and $14-16M timeline from target to IND, which is a substantial reduction compared to traditional industry timelines that can take 5.5 years from discovery to IND.
• The company's ABS-101 program, a potential best-in-class anti-TL1A antibody, is designed to achieve superior therapeutic properties over clinical competitors like MK-7240 (Merck), RVT-3101 (Roivant), and TEV-48574 (Sanofi), with the goal of extended half-life and longer dosing intervals.
• Absci's de novo AI antibody design capabilities, validated through partnerships and internal programs, position it as a leader in the field of generative AI for biologics, differentiating it from companies relying on traditional methods.
• The company's focus on cytokine biology and the development of first-in-class assets like ABS-301, derived from patient samples using Reverse Immunology, sets it apart from competitors focusing on more established targets.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash reserves, but encouraged by the progress in partnerships and pipeline development.
• Employees may be motivated by the company's progress and the potential for future growth.
• Customers and partners may be interested in the company's AI-driven drug discovery platform and its potential to accelerate drug development.
• Suppliers and creditors may be interested in the company's financial stability and future prospects.

Next Steps

• Absci plans to continue advancing its internal pipeline programs, including ABS-101, ABS-201, and ABS-301.
• The company expects to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025.
• Absci will continue to seek and secure additional drug creation partnerships.
• The company will host a conference call to discuss its third quarter 2024 results.

Key Dates

Keywords

AI, drug discovery, antibody, generative AI, biologics, partnerships, clinical trials, preclinical studies, ABS-101, ABS-201, ABS-301, oncology, immunology, TL1A, Reverse Immunology